Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders

The 2017 Annual Meeting of Stockholders of Protalix
BioTherapeutics, Inc. (the Company) was held on April 12, 2017.

Set forth below, with respect to each such matter, are the number
of votes cast for or against or withheld, as applicable, the
number of abstentions and the number of broker non-votes.

(1)Election of Directors

(2)Approval, on a non-binding, advisory basis, the compensation
of the Companys named executive officers

(3)Approval, in accordance with Section 713(a) of the NYSE MKT
Company Guide, the potential issuance of shares representing in
excess of 19.9% of the Companys pre-transaction total shares of
common stock outstanding that may result from the conversion of,
or payment of accrued interest on, the Companys outstanding
Convertible Notes

(4)Approval of an amendment to the Companys Certificate of
Incorporation, as amended, to increase the number of shares of
the Companys common stock, par value $0.001 per share, authorized
for issuance from 250,000,000 to 300,000,000

(5)Ratification of the appointment of Kesselman Kesselman

Item 8.01. Other Events

Reference is made to Item 5.07. As a result of the approval by
the Companys stockholders of proposal 3 described above, for
purposes of the Companys 7.5% convertible notes, April 12, 2017
is the Capped Combination Settlement Release Date as described in
the Indenture dated as of December 7, 2016, between the Company,
the guarantors party thereto, The Bank of New York Mellon Trust
Company, N.A., as trustee and Wilmington Savings Fund Society,
FSB, as collateral agent.

About Protalix BioTherapeutics, Inc. (NYSEMKT:PLX)

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company’s product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.

Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Recent Trading Information

Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) closed its last trading session down -0.20 at 1.11 with 2,376,097 shares trading hands.